In a recent development, Turn Therapeutics Inc. (TTRX) received a “Sell” rating from Karen Sterling of WBB Securities, effective September 14, 2026. The report not only highlights a cautionary outlook for the struggling biotech company but also places a price target of $10, notably below its current trading price of $13.45. This rating is a critical indicator for investors considering their options in what has been a turbulent market for TTRX.
Recent Price Action
The stock of Turn Therapeutics has exhibited considerable volatility lately, trading at approximately $13.45. In recent sessions, TTRX has shown an increase of $0.76, equating to a percentage change of nearly 6%. The stock’s recent movement belies a more troubling backdrop, as TTRX has a 52-week high of $49.41 and a low of $8.85. These figures reflect the stock’s steep decline from its highs, suggesting that investor sentiment has soured significantly. Trading volume has spiked with 131,355 shares exchanging hands on average—considerably exceeding its three-month average volume of 89,733. Yet, a high beta of 2.049 indicates that the stock remains more volatile than the overall market, amplifying both risks and potential rewards for traders.
[chart type=’price’ value=’TTRX’]
Historical Performance
In terms of performance, Turn Therapeutics has had a mixed track record over recent months. The past 30 days have yielded a remarkable increase of 56.08%, signaling a resurgence in investor interest. However, this short-term uptick stands in stark contrast to the quarterly performance, which has declined by 8.7%, illustrating the volatility and uncertainty plaguing the company. Year-over-year performance data adds another layer of complexity, with the stock’s long-term potential remaining a significant question mark amid fluctuating investor confidence. With weekly volatility clocking in at 11.53% and monthly volatility almost identical at 11.51%, TTRX remains a high-risk, high-reward proposition for investors.
[chart type=’performance’ value=’TTRX’]
Earnings Analysis
Recent earnings results paint a stark picture of Turn Therapeutics’ financial health. For its latest quarter, the company reported an earnings per share (EPS) of -$0.20, which fell short of analysts’ estimates of -$0.02, leading to a surprise factor of 900%. Historical data posits a substantial decline from the previous quarter, where the company reported an EPS of -$0.07 against an equivalent estimate. This negative trend in earnings not only raises concerns over the company’s operational efficiency but also suggests that the management’s guidance may have been overly optimistic.
[chart type=’income-bar-chart’ value=’TTRX’]
Analyst / Consensus View
The consensus sentiment surrounding TTRX is heavily pessimistic with only one rating provided. WBB Securities rates the stock as a “Sell,” with an average price target aligning with the firm’s price target at $10. Given that there are no buy or hold ratings, the lack of bullish sentiment further underscores the caution that investors should exercise when contemplating TTRX. The singular viewpoint from Sterling reflects a broader skepticism in the market, particularly amid the company’s disappointing earnings and prospects.
[chart type=’analyst-ratings’ value=’TTRX’]
Stock Grading or Fundamental View
Assessing TTRX through the lens of the Stocks Telegraph grading system reveals a score of 38, suggesting weak fundamentals and limited market appeal. The grading incorporates various financial metrics indicative of a company’s viability. In this case, the low score signals that Turn Therapeutics may be struggling to sustain growth or innovate effectively within its sector, a critical concern for potential investors.
[chart type=’st-cards’ value=’TTRX’]
Conclusion
For investors, the current landscape surrounding Turn Therapeutics (TTRX) commands cautious navigation. With WBB Securities issuing a “Sell” rating, today’s investors are predominantly those with a strong tolerance for risk—specifically, traders looking to capitalize on short-lived volatility may find TTRX appealing. However, the significant risks stemming from disappointing earnings and fragile investor sentiment should not be overlooked. Long-term investors, particularly those focused on stable, growth-oriented paths, may prefer to look elsewhere as Turn Therapeutics grapples with its present challenges. The potential for further decline makes TTRX a stock worth monitoring closely in the days ahead.